The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment.
about
Systematic review and meta-analysis: rapid diagnostic tests versus placental histology, microscopy and PCR for malaria in pregnant womenSpread of artemisinin resistance in Plasmodium falciparum malariaDeclining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand borderNew Fixed-Dose Artesunate-Mefloquine Formulation against Multidrug-Resistant Plasmodium falciparum in Adults: a Comparative Phase IIb Safety and Pharmacokinetic Study with Standard-Dose Nonfixed Artesunate plus MefloquineBasigin is a receptor essential for erythrocyte invasion by Plasmodium falciparumReal-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparumThe perils of PCR: can we accurately 'correct' antimalarial trials?Exposing malaria in-host diversity and estimating population diversity by capture-recapture using massively parallel pyrosequencing.Polymerase chain reaction adjustment in antimalarial trials: molecular malarkey?Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association studySustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytesRandomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparumArtesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trialStatus of potential PfATP6 molecular markers for artemisinin resistance in SurinameCharacterization of Within-Host Plasmodium falciparum Diversity Using Next-Generation Sequence DataGenetic diversity among Plasmodium falciparum field isolates in Pakistan measured with PCR genotyping of the merozoite surface protein 1 and 2.Only viable parasites are detected by PCR following clearance of rodent malarial infections by drug treatment or immune responses.Placental infections with histologically confirmed Plasmodium falciparum are associated with adverse birth outcomes in India: a cross-sectional study.Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.Different mutation patterns of Plasmodium falciparum among patients in Jimma University Hospital, Ethiopia.Antirelapse Efficacy of Various Primaquine Regimens for Plasmodium vivaxThe baseline distribution of malaria in the initial phase of elimination in Sabang Municipality, Aceh Province, Indonesia.Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia.Discontinued drugs in 2005: anti-infectives.Therapeutic efficacy of sulphadoxine-pyrimethamine and chloroquine for the treatment of uncomplicated malaria in pregnancy in Burkina Faso.Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine.The molecular epidemiology of malaria.Genetic diversity of Plasmodium vivax malaria in China and Myanmar.Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections.The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections.Intervals to Plasmodium falciparum recurrence after anti-malarial treatment in pregnancy: a longitudinal prospective cohortArtemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia.Relevance of undetectably rare resistant malaria parasites in treatment failure: experimental evidence from Plasmodium chabaudi.Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria.Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical AssessmentEfficacy of artemether-lumefantrine therapy for the treatment of uncomplicated Plasmodium falciparum malaria in Southwestern Ethiopia.Drug resistance hampers our capacity to roll back malaria.A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance of Plasmodium falciparum Following Artemisinin Treatment.
P2860
Q17485686-B661152B-29AF-4BDC-AA19-20B1CA9C628BQ21032481-78D0938D-B34C-466D-A899-F75E96565B7DQ21032539-30D7E59E-22A8-4B35-B240-102AE94849DEQ22061804-86F6E293-D48F-49B0-A77E-69C49799A96AQ24297064-AF91771E-91DE-442C-8A7D-AA8318EAF679Q24558561-9D7705EC-FA8F-4C90-825A-96C42A4669CFQ24615919-9FD67399-65DE-4E4C-9CE2-FB3792036562Q24633707-7CC869EC-2D73-4397-B940-A1BC94CB9C40Q24649683-B87BBD51-BD36-4576-BF90-1C466AD3BF51Q24805474-F42BD2CE-007B-498C-8A2C-06CF23AFF1B7Q27861941-02555608-9819-4D9C-A103-45E093B7B8D4Q28125936-BEB2F1E8-01ED-4CDB-914A-E7FDAC9F76DDQ28469026-3A08CFB5-36C7-41CB-9BF1-057ADFC05AF5Q28478138-DEF06BF6-9FB0-4336-BE06-5B30210280A7Q29353788-52FF7B52-28F2-4FA8-ADDC-7596A61FEE4CQ30303389-2788DF90-3391-4097-9186-656F8789316AQ33590165-67FCC262-DF8C-4FDE-8340-00C22DB4304DQ33758001-86EB44CA-F4A9-4604-9764-B1B0A91E9350Q33786153-5F426017-09E7-4D29-800E-D9B07500E756Q33876535-9A4D0D7E-ED8C-4024-ABE1-7F1A2F571C47Q34068703-5F04A0F2-3BCD-4070-835C-48942467417DQ34252526-4A2CE1DD-3DD0-48AA-A3F4-6216F000995BQ34386579-4BF71BF2-33F1-4BE2-B54C-344A5209568BQ34504371-855D0D80-501C-40E2-B967-1EBC709D377AQ34588892-72D04B78-CE9F-4C45-8855-38F64B4347AEQ34944810-8939614B-B6CC-47C2-9A92-8CD9D282AB2AQ34996451-8F85117C-578E-49F3-AB96-E5F99C9D733CQ35013405-992804E9-99CF-468B-9605-5D3FEBD7E1E3Q35126436-33D12AE8-5501-4947-81BB-191075408047Q35219959-582B76C2-C66B-4FA7-81C0-651EB5260D20Q35250823-19506BC7-82AA-4111-8E75-DD94FB0B47E4Q35635957-F2340516-DC25-403F-86E2-90760481D4D7Q35667005-FC927CFA-4954-4518-BA4F-3AA0B2639795Q35676996-EF01A457-4171-4997-99E9-094C4D9E8B02Q35692528-E169F1B4-0BCF-466A-A5E9-BB1C5D3F888DQ35761064-7AD20CF3-580A-4DAE-BD0E-A274071B3FA8Q35859839-2743FB61-DBEF-4A1B-A84C-6D4645AC6F36Q35954244-EDE403FA-B862-4ED9-8B16-0C61E0360C2DQ36201223-7DED622B-453B-42DA-8C94-5E6546F1F205Q36208579-C2C4BB25-5645-460B-90F4-7DFB84EEE63C
P2860
The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
The use of PCR genotyping in t ...... r antimalarial drug treatment.
@en
The use of PCR genotyping in t ...... r antimalarial drug treatment.
@nl
type
label
The use of PCR genotyping in t ...... r antimalarial drug treatment.
@en
The use of PCR genotyping in t ...... r antimalarial drug treatment.
@nl
prefLabel
The use of PCR genotyping in t ...... r antimalarial drug treatment.
@en
The use of PCR genotyping in t ...... r antimalarial drug treatment.
@nl
P1476
The use of PCR genotyping in t ...... r antimalarial drug treatment.
@en
P304
P356
10.1016/S0169-4758(98)01340-4
P577
1998-11-01T00:00:00Z